Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by 19F-Magnetic Resonance Imaging (MRI)

Weibel, Stephanie; Basse-Luesebrink, Thomas Christian; Hess, Michael; Hofmann, Elisabeth; Seubert, Carolin; Langbein-Laugwitz, Johanna; Gentschev, Ivaylo; Sturm, Volker Jörg Friedrich; Ye, Yuxiang; Kampf, Thomas; Jakob, Peter Michael; Szalay, Aladar A.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Oncolytic virotherapy of tumors is an up-coming, promising therapeutic modality of cancer therapy. Unfortunately, non-invasive techniques to evaluate the inflammatory host response to treatment are rare. Here, we evaluate 19F magnetic resonance imaging (MRI) which enables the non-invasive visualization of inflammatory processes in pathological conditions by the use of perfluorocarbon nanoemulsions (PFC) for monitoring of oncolytic virotherapy. Methodology/Principal Findings: The Vaccinia virus strain GLV-1h68 was used as an oncolytic agent for the treatment of different tumor models. Systemic application of PFC emulsions followed by 1H/19F MRI of mock-infected and GLV-1h68-infected tumor-bearing mice revealed a significant accumulation of the 19F signal in the tumor rim of virus-treated mice. Histological examination of tumors confirmed a similar spatial distribution of the 19F signal hot spots and CD68+-macrophages. Thereby, the CD68+-macrophages encapsulate the GFP-positive viral infection foci. In multiple tumor models, we specifically visualized early inflammatory cell recruitment in Vaccinia virus colonized tumors. Furthermore, we documented that the 19F signal correlated with the extent of viral spreading within tumors. Conclusions/Significance: These results suggest 19F MRI as a non-invasive methodology to document the tumor-associated host immune response as well as the extent of intratumoral viral replication. Thus, 19F MRI represents a new platform to non-invasively investigate the role of the host immune response for therapeutic outcome of oncolytic virotherapy and individual patient response.


Related Articles

  • Cancer Immunity: Lessons From Infectious Diseases. Trinchieri, Giorgio // Journal of Infectious Diseases;2015 Supplement, Vol. 212, pS67 

    Innate and adaptive immunity are activated by both infections and tumors. The immune cells infiltrating infected tissues are similar to those infiltrating neoplastic tissues, but their function in the first setting is quite different from that in the latter. Infected tissues are usually...

  • Mast cells impair the development of protective anti-tumor immunity. Wasiuk, Anna; Dalton, Dyana; Schpero, William; Stan, Radu; Conejo-Garcia, Jose; Noelle, Randolph // Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2273 

    Mast cells have emerged as critical intermediaries in the regulation of peripheral tolerance. Their presence in many precancerous lesions and tumors is associated with a poor prognosis, suggesting mast cells may promote an immunosuppressive tumor microenvironment and impede the development of...

  • Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Albertini, Mark; Hank, Jacquelyn; Gadbaw, Brian; Kostlevy, Jordan; Haldeman, Jennifer; Schalch, Heidi; Gan, Jacek; Kim, KyungMann; Eickhoff, Jens; Gillies, Stephen; Sondel, Paul // Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2261 

    Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m/day as 4-h...

  • Involvement of eosinophils in the anti-tumor response. Gatault, Solène; Legrand, Fanny; Delbeke, Marie; Loiseau, Sylvie; Capron, Monique // Cancer Immunology, Immunotherapy;Sep2012, Vol. 61 Issue 9, p1527 

    Eosinophils have long been associated with allergy and parasitic infections. Today, they are considered as multifunctional leukocytes, which participate both in innate and adaptive immune response though the expression of various receptors and mediators. Although the tumor-associated...

  • CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. De Cesare, Michelandrea; Sfondrini, Lucia; Pennati, Marzia; De Marco, Cinzia; Motta, Valentina; Tagliabue, Elda; Deraco, Marcello; Balsari, Andrea; Zaffaroni, Nadia // Journal of Translational Medicine;1/25/2016, Vol. 14, p1 

    Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and locally aggressive disease. DMPM prognosis is dismal, mainly due to the lack of effective treatment options and the development of new therapeutic strategies is urgently needed. In this context, novel...

  • Monitoring Antitumour Immune Response During Immunotherapy of Cancer: Why and How? deMatos, P.; Seigler, H.F. // BioDrugs;1999, Vol. 11 Issue 4, p239 

    Cancer remains one of the most important public health concerns facing us today. Despite recent therapeutic developments, conventional therapies have provided only limited success in the management of patients with advanced disease. The recent discovery of tumour-associated antigens has led to a...

  • Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Prijovich, Z.M.; Chen, B.-M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S.R. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1634 

    Cancer chemotherapy is limited by the modest therapeutic index of most antineoplastic drugs. Some glucuronide prodrugs may display selective anti-tumour activity against tumours that accumulate β-glucuronidase. We examined the toxicity and anti-tumour activity of 9-aminocamptothecin...

  • Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents. Tentori, Lucio; Graziani, Grazia // Current Medicinal Chemistry;Jul2002, Vol. 9 Issue 13, p1285 

    Among methylating agents of clinical interest, temozolomide is a novel antitumor compound that has raised particular interest due to its acceptable safety profile and activity against tumors poorly responsive to conventional chemotherapy, such as malignant glioma and metastatic melanoma....

  • How to starve a tumor. Gorman, Christine // Time International (South Pacific Edition);1/9/95, Issue 2, p37 

    Reports on the development of two proteins which act as blocking agents that dissolve blood vessels that provide nourishment to tumors. Scripps Research Institute scientists' discovery of a single biochemical switch that triggers the growth of blood vessels in almost all tumors in laboratory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics